Roche’s Foundation Medicine rebranded Saga Diagnostics’ MRD test and is seeking new indications beyond its initial breast cancer use, according to reporting on the test update. The assay uses patient tissue to perform whole-genome sequencing, selects structural-variant “fingerprints,” and then runs digital PCR on circulating tumor DNA to deliver individualized MRD results. The rebrand to FoundationOne MRD reflects Roche’s broader portfolio alignment and sets up commercialization in labs capable of running the digital PCR component. The approach is built around structural variants rather than point mutations, aiming to improve sensitivity and reduce sequencing-driven errors. For biotech and diagnostic companies, the update shows continued traction for tissue-informed, personalized MRD analytics—particularly when test performance can be framed through stability of the genomic targets and faster turnaround workflows.